Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

70.65 +0.31 (+0.44%)
Streaming Delayed Price Updated: 10:57 AM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Amazon To $103? Plus Piper Sandler Predicts $300 For Illumina ↗
Rosenblatt boosted the price target on Amazon.com, Inc. (NASDAQ: AMZN) from $118 to $103. Rosenblatt analyst Barton Crockett maintained the stock with a Neutral rating. Amazon shares fell 4.3% to close... 
Via Benzinga
News headline image
Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review ↗
Bitcoin hit a two-year low while Meta and Tesla were in focus. 
Via Investor's Business Daily
News headline image
Meta Platforms, Hilton Grand Vacations, D.R. Horton, And Some Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Halozyme Therapeutics Shares Jump On Better Than Expected Annual Guidance ↗
 
Via Benzinga
News headline image
Halozyme, Chugai Ink $185M ENHANZE Technology Licensing Pact ↗
Halozyme Therapeutics Inc (NASDAQ: HALO) has  
Via Benzinga
News headline image
Earnings Scheduled For February 22, 2022 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu... 
Via Benzinga
News headline image
Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗
Upgrades 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Halozyme Therapeutics: Q2 Earnings Insights ↗
  Halozyme Therapeutics (NASDAQ:HALO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
7 Biotech Stocks With Key Catalysts Coming in July ↗
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth. 
Via InvestorPlace
News headline image
Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International ↗
Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department. 
Via Benzinga
News headline image
MindMed Appoints Schond L. Greenway As CFO ↗
Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO. 
Via Benzinga
News headline image
Recap: Halozyme Therapeutics Q1 Earnings ↗
Halozyme Therapeutics (NASDAQ:HALO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Halozyme Therapeutics's Earnings Outlook ↗
Halozyme Therapeutics (NASDAQ:HALO) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Why Is Sierra Oncology (SRRA) Stock Up Today? ↗
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring. 
Via InvestorPlace
News headline image
Why Antares Pharma Stock Is Soaring Today ↗
Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing... 
Via Benzinga
News headline image
Why Is Antares Pharma (ATRS) Stock Up Today? ↗
Antares Pharma (ATRS) stock is rocketing higher on Wednesday after the company reached an acquisition agreement with Halozyme (HALO). 
Via InvestorPlace
News headline image
Benzinga's Daily Brief On Trending Tickers For April 13, 2022: JPMorgan, PayPal, Bed Bath & Beyond And More ↗
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... 
Via Benzinga
News headline image
Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares ↗
GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
News headline image
Morning Brief: Top Stories Dominating Financial Media on Wednesday, April 13 ↗
Reuters Blackrock To Introduce Its First China ETF In 2022: Reuters According to two people with close knowledge of the matter, BlackRock, Inc. (NYSE: BLK) plans to launch... 
Via Benzinga
News headline image
Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
News headline image
Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties ↗
 
Via Benzinga
News headline image
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder ↗
Argenx SE (NASDAQ: ARGX) ) has  
Via Benzinga
News headline image
Halozyme's Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline Growth ↗
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q4 revenue of $102 million compared to $121.7 million a year ago, beating the consensus of $100.32 million.... 
Via Benzinga
News headline image
Halozyme Therapeutics: Q4 Earnings Insights ↗
Halozyme Therapeutics (NASDAQ:HALO) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.